Suzuken Co Ltd (JP:9987)
:9987
Top Page
Suzuken Co
(9987)
Select Model
Select Model
Rating:69Neutral
Price Target:
¥7,023.00
▲(10.83% Upside)
Action:ReiteratedDate:08/30/25
Suzuken Co's overall stock score reflects a strong balance sheet and moderate valuation, but is tempered by significant revenue decline and cash flow challenges. Technical indicators suggest a stable market position, but the lack of earnings call data and corporate events limits further insights.
Positive Factors
Very low leverage / strong balance sheet
An almost negligible debt-to-equity ratio provides durable financial flexibility for a distribution business that needs to finance inventory and working capital. Low leverage reduces refinancing risk, supports investment in logistics, and cushions the company through industry cyclicality over months.
Negative Factors
Sharp revenue decline
A steep, persistent drop in revenue materially undermines scale advantages in distribution, reduces bargaining leverage with manufacturers, and impairs fixed-cost absorption. Over a multi-month horizon this can erode margins, service levels, and the cash conversion profile.
Read all positive and negative factors
Positive Factors
Negative Factors
Very low leverage / strong balance sheet
An almost negligible debt-to-equity ratio provides durable financial flexibility for a distribution business that needs to finance inventory and working capital. Low leverage reduces refinancing risk, supports investment in logistics, and cushions the company through industry cyclicality over months.
Read all positive factors
Suzuken Co (9987) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥340.31B
Dividend Yield1.6%
Average Volume (3M)163.97K
Price to Earnings (P/E)7.2
Beta (1Y)0.45
Revenue Growth1.37%
EPS Growth-1.55%
CountryJP
Employees13,086
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)175.46
Shares Outstanding72,167,206
10 Day Avg. Volume143,650
30 Day Avg. Volume163,966
Financial Highlights & Ratios
PEG Ratio0.40
Price to Book (P/B)0.92
Price to Sales (P/S)0.16
P/FCF Ratio-4.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥7,100.00Price Target Upside12.04% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)437.94
Revenue Forecast (FY)¥2.52T
Suzuken Co Business Overview & Revenue Model
Company Description
Suzuken Co., Ltd., together with its subsidiaries, primarily engages in the wholesale of pharmaceuticals in Japan and internationally. The company operates in four segments: Pharmaceutical Distribution Business, Pharmaceutical Manufacturing Busine...
How the Company Makes Money
Suzuken generates revenue primarily through the wholesale distribution of pharmaceutical products, which constitutes the bulk of its sales. The company has established a comprehensive supply chain, enabling efficient delivery and logistics service...
Suzuken Co Financial Statement Overview
Summary
Income Statement
75
Positive
Balance Sheet
80
Positive
Cash Flow
60
Neutral
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.41T | 2.40T | 2.39T | 2.31T | 2.24T | 2.13T |
| Gross Profit | 192.18B | 192.23B | 185.25B | 179.69B | 167.33B | 157.84B |
| EBITDA | 49.55B | 49.19B | 43.62B | 41.45B | 30.14B | 19.47B |
| Net Income | 33.32B | 34.50B | 29.02B | 20.34B | 14.39B | 7.90B |
Balance Sheet | ||||||
| Total Assets | 1.15T | 1.11T | 1.23T | 1.15T | 1.14T | 1.11T |
| Cash, Cash Equivalents and Short-Term Investments | 142.20B | 141.58B | 242.11B | 192.70B | 201.46B | 212.12B |
| Total Debt | 23.85B | 1.80B | 1.80B | 1.80B | 1.88B | 2.28B |
| Total Liabilities | 744.12B | 706.41B | 812.26B | 734.57B | 723.65B | 696.51B |
| Stockholders Equity | 402.16B | 407.29B | 416.31B | 411.21B | 417.69B | 417.05B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -79.39B | 76.41B | 22.21B | -1.64B | 10.03B |
| Operating Cash Flow | 0.00 | -65.08B | 87.22B | 37.27B | 9.52B | 15.60B |
| Investing Cash Flow | 0.00 | 20.38B | 10.35B | -46.36B | 1.44B | -14.59B |
| Financing Cash Flow | 0.00 | -35.48B | -31.72B | -26.22B | -11.60B | -7.39B |
Suzuken Co Technical Analysis
Negative
6337.00
Price Trends
6156.05
Negative
6121.77
Negative
5880.40
Positive
Market Momentum
-0.84
Negative
46.10
Neutral
46.50
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:9987, the sentiment is Negative. The current price of 6337 is above the 20-day moving average (MA) of 5965.72, above the 50-day MA of 6156.05, and above the 200-day MA of 5880.40, indicating a neutral trend. The MACD of -0.84 indicates Negative momentum. The RSI at 46.10 is Neutral, neither overbought nor oversold. The STOCH value of 46.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:9987.
Suzuken Co Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | ¥471.54B | 5.40 | 6.92% | 2.69% | 5.11% | -20.51% | |
69 Neutral | ¥340.31B | 7.24 | 8.60% | 1.60% | 1.37% | -1.55% | |
69 Neutral | ¥447.23B | 14.05 | 11.37% | 3.04% | 6.32% | 8.19% | |
68 Neutral | ¥518.75B | 9.27 | 6.39% | 2.27% | 3.88% | -10.72% | |
67 Neutral | ¥353.30B | 16.82 | ― | 0.41% | 15.81% | 27.05% | |
66 Neutral | ¥641.95B | 14.44 | 15.71% | 0.96% | 21.81% | 67.76% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
JP:9987
Suzuken Co
5,968.00
1,195.76
25.06%
JP:2784
Alfresa Holdings
2,461.00
420.39
20.60%
JP:7459
Medipal Holdings
2,833.00
581.74
25.84%
JP:9989
Sundrug Co
3,857.00
-501.89
-11.51%
JP:7649
Sugi Holdings Co
3,378.00
390.59
13.07%
JP:3549
KUSURI NO AOKI HOLDINGS CO.,LTD.
3,699.00
489.97
15.27%
Suzuken Co Corporate Events
Suzuken Nears Completion of ¥26 Billion Share Buyback Program
Mar 2, 2026
Suzuken has provided an update on its ongoing share repurchase program, disclosing that it bought back 375,900 common shares in February 2026 for a total of approximately 2.41 billion yen through market purchases on the Tokyo Stock Exchange. This ...
Suzuken Reshapes Pharmaceutical Logistics with Intra-Group Split and New Subsidiary
Feb 12, 2026
Suzuken will restructure its intra-group logistics operations by carving out S.D. Collabo’s manufacturer logistics services into a new wholly owned subsidiary, Collabo CREATE Co., Ltd., while leaving S.D. Collabo focused on its specialty dru...
Suzuken posts higher sales but weaker profits and lower equity ratio for nine months
Feb 12, 2026
Suzuken reported consolidated net sales of ¥1.89 trillion for the nine months to December 31, 2025, up 2.6% year on year, while operating and ordinary profits declined 8.6% and 5.2%, respectively. Profit attributable to owners of parent inche...
Suzuken Updates Progress on Ongoing Share Repurchase Program
Feb 2, 2026
Suzuken Co., Ltd. reported the January 2026 progress of its ongoing share repurchase program, buying back 403,200 common shares on the Tokyo Stock Exchange during the month for a total of ¥2.54 billion. Under a previously approved resolution ...
Suzuken Advances Toward Completion of ¥26 Billion Share Buyback Program
Jan 5, 2026
Suzuken Co., Ltd. reported that it repurchased 370,700 of its common shares on the Tokyo Stock Exchange during December 2025 for a total of approximately ¥2.27 billion, as part of an ongoing share buyback program authorized under Japan’...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.